ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
OBJECTIVE
A disintegrin and metalloprotease (ADAM) 9 has been implicated in tumour progression of prostate cancer. We evaluated the expression of ADAM9 on protein and messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following prostatectomy and correlated the findings with clinicopathological parameters including prostate-specific antigen (PSA) relapse times.


METHODS
We immunostained 198 clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analysed via quantitative reverse transcriptase-polymerase chain reaction.


RESULTS
ADAM9 was significantly upregulated in prostate cancer compared with normal tissue on mRNA and protein level. ADAM9 protein expression was significantly associated with shortened PSA relapse-free survival in univariate and multivariate analyses, particularly in patients who had received prior androgen ablation.


CONCLUSIONS
ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse-free survival following radical prostatectomy. Further studies are needed to verify its role as a predictive marker of response to androgen ablation.
Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Florian R
FR
Fritzsche
Monika
M
Jung
Angelika
A
Tölle
Peter
P
Wild
Arndt
A
Hartmann
Kirsten
K
Wassermann
Anja
A
Rabien
Michael
M
Lein
Manfred
M
Dietel
Christian
C
Pilarsky
Daniela
D
Calvano
Robert
R
Grützmann
Klaus
K
Jung
Glen
G
Kristiansen
D051722:ADAM Proteins / Q000096:biosynthesis / Q000235:genetics*; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000097:blood / Q000235:genetics; D015153:Blotting, Western; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000601:surgery; D012334:RNA, Neoplasm / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D012334:RNA, Neoplasm; D017430:Prostate-Specific Antigen; D051722:ADAM Proteins; C098339:ADAM9 protein, human